{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:47:17Z","timestamp":1791229637140,"version":"4.1.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH\/NCI","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40257-025-00955-7","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T01:47:25Z","timestamp":1748224045000},"page":"723-731","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cutaneous T Cell Lymphoma Following Dupilumab Therapy in Patients with Atopic Dermatitis: Clinical Review and Recommendations"],"prefix":"10.1007","volume":"26","author":[{"given":"Leore","family":"Lavin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1206-1057","authenticated-orcid":false,"given":"Shamir","family":"Geller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"issue":"2","key":"955_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/cyto.b.21888","volume":"100","author":"MP Pulitzer","year":"2021","unstructured":"Pulitzer MP, Horna P, Almeida J. S\u00e9zary syndrome and mycosis fungoides: an overview, including the role of immunophenotyping. Cytom B Clin Cytom. 2021;100(2):132\u20138. https:\/\/doi.org\/10.1002\/cyto.b.21888.","journal-title":"Cytom B Clin Cytom"},{"issue":"3","key":"955_CR2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.cll.2017.06.006","volume":"37","author":"M Pulitzer","year":"2017","unstructured":"Pulitzer M. Cutaneous T-cell lymphoma. Clin Lab Med. 2017;37(3):527\u201346. https:\/\/doi.org\/10.1016\/j.cll.2017.06.006.","journal-title":"Clin Lab Med"},{"issue":"6","key":"955_CR3","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/bjd.12909","volume":"170","author":"JJ Scarisbrick","year":"2014","unstructured":"Scarisbrick JJ, Kim YH, Whittaker SJ, et al. Prognostic factors, prognostic indices and staging in mycosis fungoides and S\u00e9zary syndrome: where are we now? Br J Dermatol. 2014;170(6):1226\u201336. https:\/\/doi.org\/10.1111\/bjd.12909.","journal-title":"Br J Dermatol"},{"issue":"9","key":"955_CR4","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/ajh.25577","volume":"94","author":"AC Hristov","year":"2019","unstructured":"Hristov AC, Tejasvi T, Wilcox RA. Mycosis fungoides and S\u00e9zary syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol. 2019;94(9):1027\u201341. https:\/\/doi.org\/10.1002\/ajh.25577.","journal-title":"Am J Hematol"},{"issue":"10","key":"955_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1159\/000509281","volume":"181","author":"M Bobrowicz","year":"2020","unstructured":"Bobrowicz M, Fassnacht C, Ignatova D, Chang YT, Dimitriou F, Guenova E. Pathogenesis and therapy of primary cutaneous T-cell lymphoma: Collegium Internationale Allergologicum (CIA) update 2020. Int Arch Allergy Immunol. 2020;181(10):733\u201345. https:\/\/doi.org\/10.1159\/000509281.","journal-title":"Int Arch Allergy Immunol"},{"issue":"4","key":"955_CR6","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.jid.2023.10.023","volume":"144","author":"ME Gumina","year":"2024","unstructured":"Gumina ME, Hooper MJ, Zhou XA, Koralov SB. Role of antigenic stimulation in cutaneous T-cell lymphomas. J Investig Dermatol. 2024;144(4):755\u201363. https:\/\/doi.org\/10.1016\/j.jid.2023.10.023.","journal-title":"J Investig Dermatol"},{"issue":"3","key":"955_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40257-017-0337-2","volume":"19","author":"S Geller","year":"2018","unstructured":"Geller S, Xu H, Lebwohl M, Nardone B, Lacouture ME, Kheterpal M. Malignancy risk and recurrence with psoriasis and its treatments: a concise update. Am J Clin Dermatol. 2018;19(3):363\u201375. https:\/\/doi.org\/10.1007\/s40257-017-0337-2.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"955_CR8","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/hon.2525","volume":"36","author":"A Klein","year":"2018","unstructured":"Klein A, Polliack A, Gafter-Gvili A. Rheumatoid arthritis and lymphoma: incidence, pathogenesis, biology, and outcome. Hematol Oncol. 2018;36(5):733\u20139. https:\/\/doi.org\/10.1002\/hon.2525.","journal-title":"Hematol Oncol"},{"issue":"6","key":"955_CR9","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jaad.2017.12.068","volume":"78","author":"ME Martinez-Escala","year":"2018","unstructured":"Martinez-Escala ME, Posligua AL, Wickless H, et al. Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol. 2018;78(6):1068\u201376. https:\/\/doi.org\/10.1016\/j.jaad.2017.12.068.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"955_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13555-023-01074-z","volume":"14","author":"MS Davis","year":"2024","unstructured":"Davis MS, Spencer RK, Johnson CE, et al. Risk of cutaneous T cell lymphoma with psoriasis biologic therapies. Dermatol Ther. 2024;14(1):15\u201330. https:\/\/doi.org\/10.1007\/s13555-023-01074-z.","journal-title":"Dermatol Ther"},{"issue":"6","key":"955_CR11","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/cas.13249","volume":"108","author":"Y Gion","year":"2017","unstructured":"Gion Y, Iwaki N, Takata K, et al. Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types. Cancer Sci. 2017;108(6):1271\u201380. https:\/\/doi.org\/10.1111\/cas.13249.","journal-title":"Cancer Sci"},{"issue":"5","key":"955_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/jamadermatol.2021.0345","volume":"157","author":"M Lam","year":"2021","unstructured":"Lam M, Zhu JW, Tadrous M, Drucker AM. Association between topical calcineurin inhibitor use and risk of cancer, including lymphoma, keratinocyte carcinoma, and melanoma: a systematic review and meta-analysis. JAMA Dermatol. 2021;157(5):549. https:\/\/doi.org\/10.1001\/jamadermatol.2021.0345.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"955_CR13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1046\/j.1365-4362.2001.01256.x","volume":"40","author":"JA Pielop","year":"2001","unstructured":"Pielop JA, Jones D, Duvic M. Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment. Int J Dermatol. 2001;40(8):505\u201311. https:\/\/doi.org\/10.1046\/j.1365-4362.2001.01256.x.","journal-title":"Int J Dermatol"},{"key":"955_CR14","doi-asserted-by":"publisher","unstructured":"Pomerantz RG, Campbell LS, Jukic DM, Geskin LJ. Posttransplant cutaneous T-cell lymphoma: case reports and review of the association of calcineurin inhibitor use with posttransplant lymphoproliferative disease risk. Arch Dermatol. 2010;146(5):513\u2013516. https:\/\/doi.org\/10.1001\/archdermatol.2010.60","DOI":"10.1001\/archdermatol.2010.60"},{"issue":"2","key":"955_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40257-022-00749-1","volume":"24","author":"L Schaefer","year":"2023","unstructured":"Schaefer L, Comfere N, Sokumbi O. Development of cutaneous T-cell lymphoma following biologic treatment: a systematic review. Am J Clin Dermatol. 2023;24(2):153\u201364. https:\/\/doi.org\/10.1007\/s40257-022-00749-1.","journal-title":"Am J Clin Dermatol"},{"issue":"24","key":"955_CR16","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1610020.","journal-title":"N Engl J Med"},{"issue":"2","key":"955_CR17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/bjd\/ljad136","volume":"189","author":"P Moghadam","year":"2023","unstructured":"Moghadam P, Tancrede E, Bouaziz JD, et al. Efficacy and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients. Br J Dermatol. 2023;189(2):244\u20136. https:\/\/doi.org\/10.1093\/bjd\/ljad136.","journal-title":"Br J Dermatol"},{"issue":"9","key":"955_CR18","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","volume":"159","author":"L Zhao","year":"2023","unstructured":"Zhao L, Wang Q, Liang G, et al. Evaluation of dupilumab in patients with bullous pemphigoid. JAMA Dermatol. 2023;159(9):953. https:\/\/doi.org\/10.1001\/jamadermatol.2023.2428.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"955_CR19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/bjd\/ljae403","volume":"192","author":"N Planella-Fontanillas","year":"2025","unstructured":"Planella-Fontanillas N, Bosch-Amate X, Jim\u00e9nez Ant\u00f3n A, et al. Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series. Br J Dermatol. 2025;192(3):501\u20139. https:\/\/doi.org\/10.1093\/bjd\/ljae403.","journal-title":"Br J Dermatol"},{"issue":"3","key":"955_CR20","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/all.15071","volume":"77","author":"E Guttman-Yassky","year":"2022","unstructured":"Guttman-Yassky E, Renert-Yuval Y, Bares J, et al. Phase 2a randomized clinical trial of dupilumab (anti-IL-4R\u03b1) for alopecia areata patients. Allergy. 2022;77(3):897\u2013906. https:\/\/doi.org\/10.1111\/all.15071.","journal-title":"Allergy"},{"issue":"24","key":"955_CR21","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1001\/jama.2024.4899","volume":"331","author":"DC Butler","year":"2024","unstructured":"Butler DC, Berger T, Elmariah S, et al. Chronic pruritus: a review. JAMA. 2024;331(24):2114\u201324. https:\/\/doi.org\/10.1001\/jama.2024.4899.","journal-title":"JAMA"},{"issue":"6","key":"955_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007324","volume":"11","author":"AMS Kuo","year":"2023","unstructured":"Kuo AMS, Gu S, Stoll J, et al. Management of immune-related cutaneous adverse events with dupilumab. J Immunother Cancer. 2023;11(6): e007324. https:\/\/doi.org\/10.1136\/jitc-2023-007324.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"955_CR23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40257-024-00866-z","volume":"25","author":"J Pach","year":"2024","unstructured":"Pach J, Valido K, Belzer A, Leventhal JS. The use of biologic agents for the treatment of cutaneous immune-related adverse events from immune checkpoint inhibitors: a review of reported cases. Am J Clin Dermatol. 2024;25(4):595\u2013607. https:\/\/doi.org\/10.1007\/s40257-024-00866-z.","journal-title":"Am J Clin Dermatol"},{"key":"955_CR24","doi-asserted-by":"publisher","unstructured":"Hollins LC, Wirth P, Fulchiero Jr GJ, Foulke GT. Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous t-cell lymphoma. Cutis. 2020;106(2):E8-E11. https:\/\/doi.org\/10.12788\/cutis.0074","DOI":"10.12788\/cutis.0074"},{"issue":"1","key":"955_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jid.2024.06.1272","volume":"145","author":"L Lavin","year":"2025","unstructured":"Lavin L, Dusza S, Geller S. Cutaneous T-cell lymphoma after dupilumab use: a real-world pharmacovigilance study of the FDA adverse event reporting system. J Investig Dermatol. 2025;145(1):211-214.e1. https:\/\/doi.org\/10.1016\/j.jid.2024.06.1272.","journal-title":"J Investig Dermatol"},{"issue":"10","key":"955_CR26","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1097\/DAD.0000000000001875","volume":"43","author":"O Sokumbi","year":"2021","unstructured":"Sokumbi O, Shamim H, Davis MDP, Wetter DA, Newman CC, Comfere N. Evolution of dupilumab-associated cutaneous atypical lymphoid infiltrates. Am J Dermatopathol. 2021;43(10):714\u201320. https:\/\/doi.org\/10.1097\/DAD.0000000000001875.","journal-title":"Am J Dermatopathol"},{"issue":"1","key":"955_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jaad.2020.03.050","volume":"83","author":"ML Espinosa","year":"2020","unstructured":"Espinosa ML, Nguyen MT, Aguirre AS, et al. Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients. J Am Acad Dermatol. 2020;83(1):197\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.050.","journal-title":"J Am Acad Dermatol"},{"key":"955_CR28","doi-asserted-by":"publisher","unstructured":"Newsom M, Hrin ML, Hamid RN, et al. Two cases of mycosis fungoides diagnosed after treatment non-response to dupilumab. Dermatol Online J. 2021;27(1):18. https:\/\/doi.org\/10.5070\/D3271052041.","DOI":"10.5070\/D3271052041"},{"issue":"7","key":"955_CR29","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/ijd.16388","volume":"62","author":"A Park","year":"2023","unstructured":"Park A, Wong L, Lang A, Kraus C, Anderson N, Elsensohn A. Cutaneous T-cell lymphoma following dupilumab use: a systematic review. Int J Dermatol. 2023;62(7):862\u201376. https:\/\/doi.org\/10.1111\/ijd.16388.","journal-title":"Int J Dermatol"},{"issue":"5","key":"955_CR30","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jaad.2022.12.001","volume":"88","author":"A Jfri","year":"2023","unstructured":"Jfri A, Smith JS, Larocca C. Diagnosis of mycosis fungoides or S\u00e9zary syndrome after dupilumab use: a systematic review. J Am Acad Dermatol. 2023;88(5):1164\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.001.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"955_CR31","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1684\/ejd.2024.4729","volume":"34","author":"K Fujii","year":"2024","unstructured":"Fujii K, Yoshizaki A, Matsuoka A, Baba N, Ohshima K, Kanekura T. Progression of CD8-positive S\u00e9zary syndrome from mycosis fungoides following dupilumab treatment. Eur J Dermatol. 2024;34(3):294\u20136. https:\/\/doi.org\/10.1684\/ejd.2024.4729.","journal-title":"Eur J Dermatol"},{"issue":"4","key":"955_CR32","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.jaad.2024.10.119","volume":"92","author":"J Accetta","year":"2025","unstructured":"Accetta J, Gioe R, Falgout L, Chastain W, Bitar C, Boh E. Cutaneous T cell lymphoma arising in patients treated with dupilumab: a case series of 18 patients. J Am Acad Dermatol. 2025;92(4):924\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2024.10.119.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"955_CR33","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1001\/jamadermatol.2023.3849","volume":"159","author":"CM Boesjes","year":"2023","unstructured":"Boesjes CM, Van Der Gang LF, Bakker DS, et al. Dupilumab-associated lymphoid reactions in patients with atopic dermatitis. JAMA Dermatol. 2023;159(11):1240. https:\/\/doi.org\/10.1001\/jamadermatol.2023.3849.","journal-title":"JAMA Dermatol"},{"key":"955_CR34","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jdcr.2022.04.023","volume":"24","author":"R Ahatov","year":"2022","unstructured":"Ahatov R, Good AJ, Joo M, Tipton S, Goodwin B, Kelly B. A rare case of aggressive cytotoxic T-cell lymphoma in a patient on dupilumab. JAAD Case Rep. 2022;24:112\u20134. https:\/\/doi.org\/10.1016\/j.jdcr.2022.04.023.","journal-title":"JAAD Case Rep"},{"key":"955_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jdcr.2023.01.008","volume":"33","author":"ZY Choo","year":"2023","unstructured":"Choo ZY, Akinyemi AA, Cibull T, Mehlis S, Waldinger JB. Angioimmunoblastic T-cell lymphoma unmasked by treatment with dupilumab. JAAD Case Rep. 2023;33:87\u201390. https:\/\/doi.org\/10.1016\/j.jdcr.2023.01.008.","journal-title":"JAAD Case Rep"},{"key":"955_CR36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jdcr.2021.09.020","volume":"18","author":"A Du-Thanh","year":"2021","unstructured":"Du-Thanh A, Gustave V, Dereure O. Lethal anaplastic large-cell lymphoma occurring in a patient treated with dupilumab. JAAD Case Rep. 2021;18:4\u20137. https:\/\/doi.org\/10.1016\/j.jdcr.2021.09.020.","journal-title":"JAAD Case Rep"},{"issue":"3","key":"955_CR37","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s12185-022-03330-y","volume":"116","author":"K Nakazaki","year":"2022","unstructured":"Nakazaki K, Yoshida M, Masamoto Y, et al. Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis. Int J Hematol. 2022;116(3):446\u201352. https:\/\/doi.org\/10.1007\/s12185-022-03330-y.","journal-title":"Int J Hematol"},{"key":"955_CR38","unstructured":"Real\u2010world evidence on the risk of cancer with anti\u2010IL\u20105 and anti\u2010IL\u20104Ra biologicals-Mota-2023-Allergy-Wiley Online Library. https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/all.15628. Accessed 24 Mar 2025."},{"issue":"2","key":"955_CR39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jaad.2024.03.039","volume":"91","author":"I Hasan","year":"2024","unstructured":"Hasan I, Parsons L, Duran S, Zinn Z. Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study. J Am Acad Dermatol. 2024;91(2):255\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2024.03.039.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"955_CR40","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.jaip.2024.11.015","volume":"13","author":"D Garate","year":"2025","unstructured":"Garate D, Thang CJ, Chang CT, et al. Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: a national database analysis. J Allergy Clin Immunol Pract. 2025;13(3):698-701.e1. https:\/\/doi.org\/10.1016\/j.jaip.2024.11.015.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"955_CR41","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40257-019-00453-7","volume":"20","author":"PP Vakharia","year":"2019","unstructured":"Vakharia PP, Silverberg JI. Adult-onset atopic dermatitis: characteristics and management. Am J Clin Dermatol. 2019;20(6):771\u20139. https:\/\/doi.org\/10.1007\/s40257-019-00453-7.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"955_CR42","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1111\/jdv.19325","volume":"37","author":"S Roenneberg","year":"2023","unstructured":"Roenneberg S, Braun SA, Garzorz-Stark N, et al. Histology-based classifier to distinguish early mycosis fungoides from atopic dermatitis. J Eur Acad Dermatol Venereol. 2023;37(11):2284\u201392. https:\/\/doi.org\/10.1111\/jdv.19325.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"955_CR43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.26760","volume":"98","author":"AC Hristov","year":"2023","unstructured":"Hristov AC, Tejasvi T, Wilcox RA. Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(1):193\u2013209. https:\/\/doi.org\/10.1002\/ajh.26760.","journal-title":"Am J Hematol"},{"issue":"2","key":"955_CR44","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/bjd.17258","volume":"181","author":"JJ Scarisbrick","year":"2019","unstructured":"Scarisbrick JJ, Quaglino P, Prince HM, et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol. 2019;181(2):350\u20137. https:\/\/doi.org\/10.1111\/bjd.17258.","journal-title":"Br J Dermatol"},{"issue":"4","key":"955_CR45","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.jaci.2022.02.015","volume":"149","author":"B Roediger","year":"2022","unstructured":"Roediger B, Schlapbach C. T cells in the skin: lymphoma and inflammatory skin disease. J Allergy Clin Immunol. 2022;149(4):1172\u201384. https:\/\/doi.org\/10.1016\/j.jaci.2022.02.015.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"955_CR46","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.jaad.2015.02.1116","volume":"72","author":"L Legendre","year":"2015","unstructured":"Legendre L, Barnetche T, Mazereeuw-Hautier J, Meyer N, Murrell D, Paul C. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis. J Am Acad Dermatol. 2015;72(6):992\u20131002. https:\/\/doi.org\/10.1016\/j.jaad.2015.02.1116.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"955_CR47","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1001\/jamadermatol.2020.1948","volume":"156","author":"KE Mansfield","year":"2020","unstructured":"Mansfield KE, Schmidt SAJ, Darvalics B, et al. Association between atopic eczema and cancer in England and Denmark. JAMA Dermatol. 2020;156(10):1086. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1948.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"955_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-071172","volume":"13","author":"MM Hedderson","year":"2023","unstructured":"Hedderson MM, Asgari MM, Xu F, et al. Rates of malignancies among patients with moderate to severe atopic dermatitis: a retrospective cohort study. BMJ Open. 2023;13(3): e071172. https:\/\/doi.org\/10.1136\/bmjopen-2022-071172.","journal-title":"BMJ Open"},{"issue":"1","key":"955_CR49","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/bjd\/ljad072","volume":"189","author":"J Wan","year":"2023","unstructured":"Wan J, Shin DB, Syed MN, et al. Malignancy risk in patients with atopic dermatitis: a population-based cohort study. Br J Dermatol. 2023;189(1):53\u201361. https:\/\/doi.org\/10.1093\/bjd\/ljad072.","journal-title":"Br J Dermatol"},{"issue":"2","key":"955_CR50","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jaad.2024.03.038","volume":"91","author":"CM Powers","year":"2024","unstructured":"Powers CM, Piontkowski AJ, Orloff J, et al. Risk of lymphoma in patients with atopic dermatitis: a case-control study in the All of Us database. J Am Acad Dermatol. 2024;91(2):344\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2024.03.038.","journal-title":"J Am Acad Dermatol"},{"key":"955_CR51","doi-asserted-by":"publisher","unstructured":"Van Haselen, Toonstra, Preesman, Van Der Putte, Bruijnzeel-Koomen, Van Vloten. S\u00e9zary syndrome in a young man with severe atopic dermatitis: S\u00e9zary syndrome and atopic dermatitis. Br J Dermatol. 1999;140(4):704\u20137. https:\/\/doi.org\/10.1046\/j.1365-2133.1999.02775.x.","DOI":"10.1046\/j.1365-2133.1999.02775.x"},{"issue":"2","key":"955_CR52","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000182251","volume":"218","author":"N Meyer","year":"2009","unstructured":"Meyer N, Mazereeuw-Hautier J, Launay F, Lamant L, Paul C. Cutaneous T cell lymphoma complicating severe atopic dermatitis. Dermatology. 2009;218(2):168\u201371. https:\/\/doi.org\/10.1159\/000182251.","journal-title":"Dermatology"},{"issue":"2","key":"955_CR53","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.1067\/mjd.2002.106357","volume":"47","author":"B Kirbya","year":"2002","unstructured":"Kirbya B, Owena CM, Blewittb RW, Yatesa VM. Cutaneous T-cell lymphoma developing in a patient on cyclosporin therapy. J Am Acad Dermatol. 2002;47(2):S165\u20137. https:\/\/doi.org\/10.1067\/mjd.2002.106357.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"955_CR54","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/j.1365-2133.2003.05551.x","volume":"149","author":"K Mehrany","year":"2003","unstructured":"Mehrany K, El-Azhary RA, Bouwhuis SA, Pittelkow MR. Cutaneous T-cell lymphoma and atopy: is there an association? Br J Dermatol. 2003;149(5):1013\u20137. https:\/\/doi.org\/10.1111\/j.1365-2133.2003.05551.x.","journal-title":"Br J Dermatol"},{"key":"955_CR55","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/978-3-642-59410-6_32","volume":"160","author":"G Burg","year":"2002","unstructured":"Burg G, Kempf W, Haeffner A, et al. From inflammation to neoplasia: new concepts in the pathogenesis of cutaneous lymphomas. Recent Results Cancer Res Fortschritte Krebsforsch Progres Dans Rech Sur Cancer. 2002;160:271\u201380. https:\/\/doi.org\/10.1007\/978-3-642-59410-6_32.","journal-title":"Recent Results Cancer Res Fortschritte Krebsforsch Progres Dans Rech Sur Cancer"},{"issue":"s1","key":"955_CR56","doi-asserted-by":"publisher","first-page":"105S","DOI":"10.1111\/1523-1747.ep12316249","volume":"105","author":"GS Wood","year":"1995","unstructured":"Wood GS. Lymphocyte activation in cutaneous T-cell lymphoma. J Investig Dermatol. 1995;105(s1):105S-109S. https:\/\/doi.org\/10.1111\/1523-1747.ep12316249.","journal-title":"J Investig Dermatol"},{"issue":"13","key":"955_CR57","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1182\/blood.2018888107","volume":"134","author":"LM Lindahl","year":"2019","unstructured":"Lindahl LM, Willerslev-Olsen A, Gjerdrum LMR, et al. Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. Blood. 2019;134(13):1072\u201383. https:\/\/doi.org\/10.1182\/blood.2018888107.","journal-title":"Blood"},{"key":"955_CR58","doi-asserted-by":"publisher","unstructured":"Bocklud BE, Roberts LT, Roberts DT, et al. Topical medications for atopic dermatitis and effects on increasing lymphoma risks. Cureus. Published online 20 November 2023. https:\/\/doi.org\/10.7759\/cureus.49135.","DOI":"10.7759\/cureus.49135"},{"issue":"3","key":"955_CR59","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000095044","volume":"213","author":"F Mougel","year":"2006","unstructured":"Mougel F, Dalle S, Balme B, Houot R, Thomas L. Aggressive CD30 large cell lymphoma after cyclosporine given for putative atopic dermatitis. Dermatology. 2006;213(3):239\u201341. https:\/\/doi.org\/10.1159\/000095044.","journal-title":"Dermatology"},{"issue":"4","key":"955_CR60","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.clml.2020.11.007","volume":"21","author":"EC Vonderheid","year":"2021","unstructured":"Vonderheid EC, Hamilton RG, Kadin ME. Mycosis fungoides and its relationship to atopy, serum total IgE, and eosinophil counts. Clin Lymphoma Myeloma Leuk. 2021;21(4):279-288.e7. https:\/\/doi.org\/10.1016\/j.clml.2020.11.007.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"955_CR61","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-12-3488","volume":"19","author":"E Guenova","year":"2013","unstructured":"Guenova E, Watanabe R, Teague JE, et al. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res. 2013;19(14):3755\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3488.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"955_CR62","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1182\/blood-2014-07-590398","volume":"125","author":"LJ Geskin","year":"2015","unstructured":"Geskin LJ, Viragova S, Stolz DB, Fuschiotti P. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood. 2015;125(18):2798\u2013805. https:\/\/doi.org\/10.1182\/blood-2014-07-590398.","journal-title":"Blood"},{"issue":"2","key":"955_CR63","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/life14020245","volume":"14","author":"R Mazzetto","year":"2024","unstructured":"Mazzetto R, Miceli P, Tartaglia J, Ciolfi C, Sernicola A, Alaibac M. Role of IL-4 and IL-13 in cutaneous T cell lymphoma. Life. 2024;14(2):245. https:\/\/doi.org\/10.3390\/life14020245.","journal-title":"Life"},{"issue":"1","key":"955_CR64","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-021-00296-9","volume":"7","author":"R Dummer","year":"2021","unstructured":"Dummer R, Vermeer MH, Scarisbrick JJ, et al. Cutaneous T cell lymphoma. Nat Rev Dis Primer. 2021;7(1):61. https:\/\/doi.org\/10.1038\/s41572-021-00296-9.","journal-title":"Nat Rev Dis Primer"},{"issue":"12","key":"955_CR65","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1038\/s41590-024-02018-1","volume":"25","author":"R Li","year":"2024","unstructured":"Li R, Strobl J, Poyner EFM, et al. Cutaneous T cell lymphoma atlas reveals malignant TH2 cells supported by a B cell-rich tumor microenvironment. Nat Immunol. 2024;25(12):2320\u201330. https:\/\/doi.org\/10.1038\/s41590-024-02018-1.","journal-title":"Nat Immunol"},{"issue":"10","key":"955_CR66","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1111\/jdv.15075","volume":"32","author":"DJ Lewis","year":"2018","unstructured":"Lewis DJ, Huang S, Duvic M. Inflammatory cytokines and peripheral mediators in the pathophysiology of pruritus in cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol. 2018;32(10):1652\u20136. https:\/\/doi.org\/10.1111\/jdv.15075.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"955_CR67","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40257-023-00823-2","volume":"25","author":"G Biazus Soares","year":"2024","unstructured":"Biazus Soares G, Guitart J, Yosipovitch G. What\u2019s new in cutaneous T-cell lymphoma-associated pruritus. Am J Clin Dermatol. 2024;25(1):67\u201377. https:\/\/doi.org\/10.1007\/s40257-023-00823-2.","journal-title":"Am J Clin Dermatol"},{"issue":"10086","key":"955_CR68","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, De Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(17)31191-1.","journal-title":"Lancet"},{"issue":"5","key":"955_CR69","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M De Bruin-Weller","year":"2018","unstructured":"De Bruin-Weller M, Tha\u00e7i D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial. Br J Dermatol. 2018;178(5):1083\u2013101. https:\/\/doi.org\/10.1111\/bjd.16156.","journal-title":"Br J Dermatol"},{"issue":"16","key":"955_CR70","doi-asserted-by":"publisher","first-page":"adv00271","DOI":"10.2340\/00015555-3576","volume":"100","author":"I Lazaridou","year":"2020","unstructured":"Lazaridou I, Ram-Wolff C, Bouaziz J, et al. Dupilumab treatment in two patients with cutaneous T-cell lymphomas. Acta Derm Venereol. 2020;100(16):adv00271. https:\/\/doi.org\/10.2340\/00015555-3576.","journal-title":"Acta Derm Venereol"},{"key":"955_CR71","doi-asserted-by":"publisher","unstructured":"Mollanazar NK, Savage KT, Pousti BT, et al. Cutaneous T-cell lymphoma and concomitant atopic dermatitis responding to dupilumab. Cutis. 2020;106(3):131-132. https:\/\/doi.org\/10.12788\/cutis.0066.","DOI":"10.12788\/cutis.0066"},{"issue":"6","key":"955_CR72","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/jdv.17001","volume":"35","author":"O Steck","year":"2021","unstructured":"Steck O, Bertschi NL, Luther F, et al. Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with S\u00e9zary syndrome. J Eur Acad Dermatol Venereol. 2021;35(6):1331\u20137. https:\/\/doi.org\/10.1111\/jdv.17001.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"955_CR73","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1007\/s00403-023-02652-z","volume":"315","author":"A Hamp","year":"2023","unstructured":"Hamp A, Hanson J, Schwartz RA, Lambert WC, Alhatem A. Dupilumab-associated mycosis fungoides: a cross-sectional study. Arch Dermatol Res. 2023;315(9):2561\u20139. https:\/\/doi.org\/10.1007\/s00403-023-02652-z.","journal-title":"Arch Dermatol Res"},{"key":"955_CR74","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jdcr.2020.12.010","volume":"8","author":"K Russomanno","year":"2021","unstructured":"Russomanno K, Carver DeKlotz CM. Acceleration of cutaneous T-cell lymphoma following dupilumab administration. JAAD Case Rep. 2021;8:83\u20135. https:\/\/doi.org\/10.1016\/j.jdcr.2020.12.010.","journal-title":"JAAD Case Rep"},{"key":"955_CR75","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jdcr.2023.05.025","volume":"38","author":"M Toker","year":"2023","unstructured":"Toker M, Srivastava P, Amin B, Wu B. Did dupilumab unmask smoldering mycosis fungoides? JAAD Case Rep. 2023;38:11\u20133. https:\/\/doi.org\/10.1016\/j.jdcr.2023.05.025.","journal-title":"JAAD Case Rep"},{"key":"955_CR76","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jdcr.2021.05.037","volume":"14","author":"NA Trum","year":"2021","unstructured":"Trum NA, Zain J, Abad C, Rosen ST, Querfeld C. Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash. JAAD Case Rep. 2021;14:37\u201342. https:\/\/doi.org\/10.1016\/j.jdcr.2021.05.037.","journal-title":"JAAD Case Rep"},{"key":"955_CR77","doi-asserted-by":"publisher","unstructured":"Cabrera-Perez JS, Carey VJ, Odejide OO, et al. Integrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma unmasking or progression with dupilumab therapy. J Allergy Clin Immunol. Published online 7 November 2024:S0091-6749(24)01172-2. https:\/\/doi.org\/10.1016\/j.jaci.2024.10.028.","DOI":"10.1016\/j.jaci.2024.10.028"},{"key":"955_CR78","doi-asserted-by":"publisher","first-page":"adv00766","DOI":"10.2340\/actadv.v102.2234","volume":"102","author":"M Hashimoto","year":"2022","unstructured":"Hashimoto M, Miyagaki T, Komaki R, Takeuchi S, Kadono T. Development of nodular lesions after dupilumab therapy in erythrodermic mycosis fungoides with interleukin-13 receptor alpha2 expression. Acta Derm Venereol. 2022;102:adv00766. https:\/\/doi.org\/10.2340\/actadv.v102.2234.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"955_CR79","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1016\/j.jaad.2023.01.047","volume":"88","author":"TP Joshi","year":"2023","unstructured":"Joshi TP, Duvic M. Unmasking a masquerader: mycosis fungoides unveiled after dupilumab treatment. J Am Acad Dermatol. 2023;88(6):e305\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2023.01.047.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"955_CR80","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","volume":"156","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol. 2020;156(4):411. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0079.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"955_CR81","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","volume":"159","author":"AS Paller","year":"2023","unstructured":"Paller AS, Flohr C, Cork M, et al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol. 2023;159(6):596. https:\/\/doi.org\/10.1001\/jamadermatol.2023.0627.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"955_CR82","doi-asserted-by":"publisher","first-page":"e241","DOI":"10.1016\/j.jaad.2022.05.069","volume":"87","author":"JM Cohen","year":"2022","unstructured":"Cohen JM, Damsky W, Girardi M. Comment on \u201cDiagnostic testing of eczematous dermatitis with incomplete response to dupilumab.\u201d J Am Acad Dermatol. 2022;87(6):e241\u20132. https:\/\/doi.org\/10.1016\/j.jaad.2022.05.069.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"955_CR83","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1080\/14740338.2024.2410434","volume":"23","author":"Z Yang","year":"2024","unstructured":"Yang Z, Tang K, Chen J. Post-marketing safety of tralokinumab: a real-world pharmacovigilance study based on the FDA adverse event reporting system. Expert Opin Drug Saf. 2024;23(11):1439\u201346. https:\/\/doi.org\/10.1080\/14740338.2024.2410434.","journal-title":"Expert Opin Drug Saf"},{"key":"955_CR84","doi-asserted-by":"publisher","unstructured":"Basrai S, Gomez-Lara AR, Dahabreh D, et al. Mycosis fungoides unmasked by tralokinumab treatment for atopic dermatitis. JAAD Case Rep. 17 April 2025. https:\/\/doi.org\/10.1016\/j.jdcr.2025.03.030.","DOI":"10.1016\/j.jdcr.2025.03.030"},{"issue":"11","key":"955_CR85","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1001\/jamadermatol.2023.3846","volume":"159","author":"J Guitart","year":"2023","unstructured":"Guitart J. Dupilumab, atopic dermatitis, and mycosis fungoides\u2014new insights on an evolving story. JAMA Dermatol. 2023;159(11):1177\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2023.3846.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"955_CR86","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1111\/jdv.20053","volume":"38","author":"H Kook","year":"2024","unstructured":"Kook H, Gwag HE, Park SY, et al. Detecting T-cell receptor clonality in patients with severe atopic dermatitis refractory to dupilumab. J Eur Acad Dermatol Venereol. 2024;38(10):1939\u201346. https:\/\/doi.org\/10.1111\/jdv.20053.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"955_CR87","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.jaci.2024.07.019","volume":"154","author":"SY Tsai","year":"2024","unstructured":"Tsai SY, Phipatanakul W, Hawryluk EB, et al. Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: a population-based cohort study. J Allergy Clin Immunol. 2024;154(5):1195\u2013203. https:\/\/doi.org\/10.1016\/j.jaci.2024.07.019.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"955_CR88","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1001\/jamadermatol.2024.1536","volume":"160","author":"LA Beck","year":"2024","unstructured":"Beck LA, Bissonnette R, Deleuran M, Nakahara T, Galus R, Coleman A, Gherardi G, Xiao J, Dingman R, Xu C, Avetisova E. Dupilumab in adults with moderate to severe atopic dermatitis: a 5-year open-label extension study. JAMA Dermatol. 2024;160(8):805\u201312. https:\/\/doi.org\/10.1001\/jamadermatol.2024.1536.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"955_CR89","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jaad.2024.04.026","volume":"91","author":"J Zhang","year":"2024","unstructured":"Zhang J, Boesjes CM, Loman L, Kamphuis E, Romeijn ML, Spekhorst LS, Haeck I, van der Gang LF, Dekkers CC, van der Rijst LP, Oosting AJ. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay registry. J Am Acad Dermatol. 2024;91(2):300\u201311. https:\/\/doi.org\/10.1016\/j.jaad.2024.04.026.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"955_CR90","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1093\/ced\/llad277","volume":"48","author":"S Buffon","year":"2023","unstructured":"Buffon S, Alberti Violetti S, Avallone G, et al. Mycosis fungoides and S\u00e9zary syndrome following dupilumab treatment: experience of two Italian tertiary care centres. Clin Exp Dermatol. 2023;48(12):1376\u20138. https:\/\/doi.org\/10.1093\/ced\/llad277.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"955_CR91","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jid.2024.08.015","volume":"145","author":"M Beylot-Barry","year":"2025","unstructured":"Beylot-Barry M, Staumont-Salle D. Cutaneous T-cell lymphoma and dupilumab use: a multifactorial and complex story. J Investig Dermatol. 2025;145(1):9\u201311. https:\/\/doi.org\/10.1016\/j.jid.2024.08.015.","journal-title":"J Investig Dermatol"},{"key":"955_CR92","doi-asserted-by":"publisher","unstructured":"Ong PY. Is dupilumab use in atopic dermatitis associated with cutaneous T-cell lymphoma? J Allergy Clin Immunol. Published online 13 February 2025:S0091-6749(25)00161-7. https:\/\/doi.org\/10.1016\/j.jaci.2025.02.002.","DOI":"10.1016\/j.jaci.2025.02.002"},{"issue":"6","key":"955_CR93","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.jaad.2024.08.057","volume":"91","author":"ZJK Neubauer","year":"2024","unstructured":"Neubauer ZJK, Brunner PM, Geskin LJ, Guttman E, Lipner SR. Decoupling the association of dupilumab with cutaneous T-cell lymphoma. J Am Acad Dermatol. 2024;91(6):1296\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2024.08.057.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"955_CR94","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jaad.2005.08.057","volume":"53","author":"N Pimpinelli","year":"2005","unstructured":"Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53(6):1053\u201363. https:\/\/doi.org\/10.1016\/j.jaad.2005.08.057.","journal-title":"J Am Acad Dermatol"},{"key":"955_CR95","doi-asserted-by":"publisher","unstructured":"Liao V, Lavin L, Pulitzer MP, Stuver R, Geller S. Diagnosis of cutaneous T-cell lymphoma following exposure to biologic agents for atopic dermatitis: a retrospective cohort study from a single tertiary cancer center. J Am Acad Dermatol. Published online 1 February 2025:S0190-9622(25)00188-4. https:\/\/doi.org\/10.1016\/j.jaad.2025.01.088.","DOI":"10.1016\/j.jaad.2025.01.088"},{"key":"955_CR96","doi-asserted-by":"publisher","unstructured":"Stuver R, Dusza S, Epstein\u2010Peterson ZD, et al. Cutaneous T\u2010cell lymphoma and dupilumab use: a retrospective matched cohort study of clinical characteristics and treatment outcomes. J Eur Acad Dermatol Venereol. 2025;39(2):e114-e117. https:\/\/doi.org\/10.1111\/jdv.20141.","DOI":"10.1111\/jdv.20141"},{"issue":"10","key":"955_CR97","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1111\/jdv.20263","volume":"38","author":"OE Akilov","year":"2024","unstructured":"Akilov OE. The odyssey of diagnosis of mycosis fungoides: sailing beyond clonality and histology. J Eur Acad Dermatol Venereol. 2024;38(10):1844\u20135. https:\/\/doi.org\/10.1111\/jdv.20263.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"955_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2023.100214","volume":"3","author":"MAX Tollenaere","year":"2023","unstructured":"Tollenaere MAX, M\u00f8lck C, Henderson I, et al. Tralokinumab effectively disrupts the IL-13\/IL-13R\u03b11\/IL-4R\u03b1 signaling complex but not the IL-13\/IL-13R\u03b12 complex. JID Innov. 2023;3(5): 100214. https:\/\/doi.org\/10.1016\/j.xjidi.2023.100214.","journal-title":"JID Innov"},{"issue":"7","key":"955_CR99","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s13555-023-00947-7","volume":"13","author":"AJ Okragly","year":"2023","unstructured":"Okragly AJ, Ryuzoji A, Wulur I, et al. Binding, neutralization and internalization of the interleukin-13 antibody, lebrikizumab. Dermatol Ther. 2023;13(7):1535\u201347. https:\/\/doi.org\/10.1007\/s13555-023-00947-7.","journal-title":"Dermatol Ther"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00955-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00955-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00955-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T20:02:36Z","timestamp":1757966556000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00955-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":99,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["955"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00955-7","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"12 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by the NIH\/NCI Cancer Center (support grant P30 CA008748).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Authors L.L. and S.G. declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"No datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Authors L.L. and S.G. reviewed literature, collected the data, and wrote the manuscript. In addition, S.G. revised the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}